保肝药预防抗肿瘤药物肝损伤用药合理性评价

详细信息    查看全文 | 推荐本文 |

英文篇名：Evaluation on Rationality of Hepatoprotective Drugs for Preventing Liver Injury Caused by Antitumor Drugs 作者：吴丽芳 ; 卓双塔 ; 林涛 英文作者：WU Lifang;ZHUO Shuangta;LIN Tao;Department of Pharmacy,The Second Hospital of Xiamen Medical College; 关键词：临床药师 ; 合理用药 ; 保肝药 ; 预防 ; 抗肿瘤药物 ; 肝损伤 ; 药学干预 英文关键词：clinical pharmacists;;rational drug use;;hepatoprotective drugs;;prevention;;antitumor drugs;;liver injury;;pharmaceutical intervention 中文刊名：YYGZ 英文刊名：China Pharmaceuticals 机构：厦门医学院附属第二医院药学部; 出版日期：2019-01-20 出版单位：中国药业 年：2019 期：v.28;No.477 语种：中文; 页：YYGZ201902029 页数：3 CN：02 ISSN：50-1054/R 分类号：94-96

摘要

目的促进临床合理使用保肝药。方法选取2017年3月至6月临床药师干预前的肿瘤化学治疗(简称化疗)住院患者156例作为对照组,另选取2017年8月至11月临床药师干预后的肿瘤化疗住院患者112例作为干预组。对比两组患者的一般资料及保肝药不合理预防性使用情况。结果干预组保肝药不合理预防性使用率为27.68%,明显低于对照组的56.41%(P <0.05),且干预组各项不合理情况均显著少于对照组(P <0.05);两组患者肝损伤发生率相当(13.46%比19.64%,P> 0.05)。结论保肝药无明显预防抗肿瘤药肝损伤作用,临床应慎重预防性使用。
        Objective To promote the rational use of hepatoprotective drugs in clinic.Methods Totally 156 in-patients undergoing cancer chemotherapy before intervention by clinical pharmacists from March to June in 2017 were selected as the control group,and 112in-patients undergoing cancer chemotherapy after intervention by clinical pharmacists from August to November in 2017 were selected as the intervention group.The general informations of the patients and the irrational preventive use of hepatoprotective drugs in the two groups were compared.Results The irrational preventive use rate of hepatoprotective drugs in the intervention group was 27.68%,which was significantly lower than 56.41% in the control group(P < 0.05),and all the irrational situations of intervention group were significantly few than those of the control group(P < 0.05).The incidence rate of liver injury caused by chemotherapy was similar between the two groups(13.46% vs.19.64%,P > 0.05).Conclusion Hepatoprotective drugs have no obvious effect on preventing liver injury caused by antitumor drugs,so they should be used cautiously in clinic.

引文

[1]BERNAL W,AUZINGER G,DHAWAN A,et al. Acute liver failure[J].Lancet,2010,376(9736):190-201.
    [2]于世英,姚阳.肿瘤药物相关性肝损伤防治专家共识(2014年版)[M].北京:中国协和医科大学出版社,2014:1-2.
    [3]陈瑜.血液病患者药物性肝损伤的预防和规范化治疗专家共识[J].中华血液学杂志,2012,33(3):252-256.
    [4]朱月萍,钱峰,朱伟,等.复方甘草酸苷与还原型谷胱联用对药物性肝损伤患者肝功能指标改善作用的疗效评价[J].抗感染药学,2017,14(5):995-997.
    [5]方巧红,罗敏,龙昌群,等.多烯磷脂酰胆碱联合护理干预治疗外伤性肝破裂术后肝损伤41例[J].中国药业,2015,24(15):113-115.
    [6]中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].临床肝胆杂志,2015,31(11):1752-1768.
    [7]房澍名,龚新雷,秦叔逵,等.新型甘草酸制剂预防抗肿瘤药物肝损伤的现状和进展[J].临床肿瘤杂志,2013,18(9):833-841.
    [8]吴婷婷,赵本慧,智俊娜,等.保肝药在雷替曲塞联合化疗中能否降低转氨酶的临床观察[J].药学与临床研究,2014,22(1):80-82.
    [9]蓝东,甘廷庆,王莉,等.预防性保肝对乳腺癌化疗所致药物性肝损伤的应用价值[J].广西医科大学学报,2O15,32(2):281-283.
    [10]毛敏,李伟,王巍,等.甘草制剂导致不良反应93例病例分析[J].中国中药杂志,2013,38(22):3768-3772.
    [11]国家药典委员会.中华人民共和国药典临床用药须知-化学药和生物制品(2015年版)[M].北京:中国医药科技出版社,2015:622-852.
    [12]陆新谦,金有豫,汤光,等.新编药物学[M].第17版.北京:人民卫生出版社,2011:34-134.